Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Polyarticular Course Juvenile Idiopathic Arthritis
NCT02592434Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of tofacitinib oral solution in juvenile idiopathic arthritis (JIA), sponsored by Pfizer. Started Jun 2016; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT02592434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592434.